King of Prussia, PA-based Prism Pharmaceuticals has received up to $68 million in capital from Paul Capital Partners' Paul Royalty Fund and Essex Woodlands Health Ventures Fund VI. Prism garnered $23 million up front through the sale of preferred stock to both Paul Capital and Essex. The company could get an additional $45 million if it reaches certain milestones. According to Warren Cooper, President and CEO of Prism, the funding will be used to help the company license products in various stages of development. Prism makes acute care cardiovascular products.
- see this press release for more on the funding
PLUS: Generic drug manufacturer and distributor Interpharm has completed a $10 million capital financing deal with Aisling Capital. Release